This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Mirati Therapeutics Croissance future

Future contrôle des critères 2/6

Mirati Therapeutics is forecast to grow earnings and revenue by 29.9% and 42.2% per annum respectively. EPS is expected to grow by 33% per annum. Return on equity is forecast to be -155.2% in 3 years.

Informations clés

29.9%

Taux de croissance des bénéfices

33.0%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.5%
Taux de croissance des recettes	42.2%
Rendement futur des capitaux propres	-155.2%
Couverture par les analystes	Good
Dernière mise à jour	20 Dec 2023

Mises à jour récentes de la croissance future

Recent updates

We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Oct 05

Is Mirati Therapeutics (NASDAQ:MRTX) In A Good Position To Invest In Growth?

Jun 22

Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

May 17

We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Feb 01

Some Analysts Just Cut Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates

Dec 09

We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth

Oct 08

Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?

Sep 11

Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

Aug 08

Mirati: Not Looking Good In 2022, But Stronger Prospects In 2-3 Years

Jun 21

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:MRTX - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	495	-408	33	-94	8
12/31/2025	312	-556	-271	-261	13
12/31/2024	173	-670	-448	-447	17
12/31/2023	62	-694	-553	-551	17
9/30/2023	38	-726	-596	-594	N/A
6/30/2023	27	-738	-591	-588	N/A
3/31/2023	19	-737	-604	-600	N/A
12/31/2022	12	-741	-575	-571	N/A
9/30/2022	12	-738	-586	-580	N/A
6/30/2022	78	-645	-496	-489	N/A
3/31/2022	73	-634	-449	-439	N/A
12/31/2021	72	-582	-399	-389	N/A
9/30/2021	74	-483	-336	-327	N/A
6/30/2021	13	-491	-365	-357	N/A
3/31/2021	13	-407	-328	-323	N/A
12/31/2020	13	-358	-276	-272	N/A
9/30/2020	12	-329	-241	-237	N/A
6/30/2020	2	-296	-196	-193	N/A
3/31/2020	2	-259	-174	-172	N/A
12/31/2019	3	-213	-149	-148	N/A
9/30/2019	6	-169	-127	-127	N/A
6/30/2019	5	-142	-114	-114	N/A
3/31/2019	5	-125	-97	-97	N/A
12/31/2018	13	-98	-70	-70	N/A
9/30/2018	9	-88	-63	-63	N/A
6/30/2018	9	-77	-58	-58	N/A
3/31/2018	9	-67	-55	-54	N/A
12/31/2017	N/A	-70	-65	-65	N/A
9/30/2017	N/A	-72	-67	-67	N/A
6/30/2017	N/A	-75	N/A	-70	N/A
3/31/2017	N/A	-79	N/A	-69	N/A
12/31/2016	N/A	-83	N/A	-68	N/A
9/30/2016	N/A	-82	N/A	-68	N/A
6/30/2016	N/A	-81	N/A	-65	N/A
3/31/2016	N/A	-75	N/A	-58	N/A
12/31/2015	N/A	-65	N/A	-51	N/A
9/30/2015	N/A	-57	N/A	-43	N/A
6/30/2015	N/A	-46	N/A	-37	N/A
3/31/2015	N/A	-42	N/A	-34	N/A
12/31/2014	N/A	-44	N/A	-33	N/A
9/30/2014	N/A	-45	N/A	-32	N/A
6/30/2014	N/A	-65	N/A	-27	N/A
3/31/2014	N/A	-62	N/A	-31	N/A
12/31/2013	N/A	-53	N/A	-29	N/A
9/30/2013	N/A	-48	N/A	-27	N/A
6/30/2013	N/A	-24	N/A	-26	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: MRTX is forecast to remain unprofitable over the next 3 years.

Bénéfices vs marché: MRTX is forecast to remain unprofitable over the next 3 years.

Croissance élevée des bénéfices: MRTX is forecast to remain unprofitable over the next 3 years.

Chiffre d'affaires vs marché: MRTX's revenue (42.2% per year) is forecast to grow faster than the US market (8.1% per year).

Croissance élevée des revenus: MRTX's revenue (42.2% per year) is forecast to grow faster than 20% per year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: MRTX is forecast to be unprofitable in 3 years.

This company has been acquired

Mirati Therapeutics Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Price target increased by 9.7% to US$60.00

Price target decreased by 8.0% to US$60.64

Consensus revenue estimates increase by 23%

Consensus revenue estimates decrease by 28%

Price target decreased to US$91.40

Consensus revenue estimates increase by 48%

Recent updates

Mirati Therapeutics, Inc. Files Form 15

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from NASDAQ Biotechnology Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Mirati Therapeutics, Inc. Receives Positive Opinion from CHMP for KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation Following a Re-Examination Procedure

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Mirati Therapeutics, Inc. Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Price target increased by 9.7% to US$60.00

Sanofi Reportedly Explores Potential Acquisition of Mirati Therapeutics

New major risk - Share price stability

We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Mirati Therapeutics, Inc. Announces CFO Changes Effective as of September 8, 2023

Insufficient new directors

Mirati Therapeutics, Inc. Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers Through Novel Approach to MTA-Cooperative PRMT5 Inhibition

Second quarter 2023 earnings: EPS exceeds analyst expectations

Mirati Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Mirati Therapeutics Provides Update on Regulatory Review in the European Union of Krazati (Adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with A Krasg12c Mutation

Price target decreased by 8.0% to US$60.64

New minor risk - Insider selling

Mirati Therapeutics Appoints Carol Gallagher, Pharm.D. as New Independent Director

Is Mirati Therapeutics (NASDAQ:MRTX) In A Good Position To Invest In Growth?

Chief Financial Officer recently sold US$172k worth of stock

Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO(R)

Insufficient new directors

Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

Consensus revenue estimates increase by 23%

Consensus revenue estimates decrease by 28%

Mirati Therapeutics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

CEO & Director recently sold US$135k worth of stock

Mirati Therapeutics, Inc. Announces U.S. Food and Drug Administration Clears the Investigational New Drug (Ind) Application of MRTX1133

Founder recently sold US$170k worth of stock

Executive VP & Chief Scientific Officer recently sold US$104k worth of stock

Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer

Mirati Therapeutics, Inc. Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Some Analysts Just Cut Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates

Price target decreased to US$91.40

Executive VP & Chief Scientific Officer recently sold US$156k worth of stock

Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Mirati Therapeutics, Inc. Announces Update for the Phase 3 SAPPHIRE Study

Founder exercised options and sold US$5.7m worth of stock

Mirati Therapeutics Reportedly Seen as Takeover Target Once Again

Consensus revenue estimates increase by 48%

Mirati Therapeutics, Inc. Announces Management Changes

Mirati Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth

Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?

Mirati: A Potential Blockbuster Stock, Will Need Patience

Mirati Therapeutics, Inc. Presents Late-Breaking Adagrasib Monotherapy and Combination

Mirati jumps 11% as Amgen meets key goal for rival cancer drug

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 15%

Mirati gains as Amgen posts new combination data for rival cancer drug

Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

Mirati Therapeutics, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Mirati: Not Looking Good In 2022, But Stronger Prospects In 2-3 Years

Mirati Therapeutics, Inc. Announces Results of A Prospective Analysis from the Phase 1B Cohort of the KRYSTAL-1

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance